The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
To evaluate the effect of deferasirox in human myeloid leukemia cells, and to identify the moleclular pathways responsible for antiproliferative effects on leukemia cells during chelation therapy, we performed gene expression profiling to focus on the pathway involved in the anticancer effect of deferasirox. The inhibitory concentration (IC 50) of deferasirox was 17–50 µM in three human myeloid cell lines (K562, U937, and HL60), while those in fresh leukemia cells obtained from four patients it varied from 88 to 172 µM. Gene expression profiling using Affymerix GeneChips (U133 Plus 2.0) revealed up‐regulation of cyclin‐dependent kinase inhibitor 1A (CDKN1A) encoding p21 CIP, genes regulating interferon (i.e. IFIT1). Pathways related to iron metabolism and hypoxia such as growth differentiation factor 15 (GDF‐15) and Regulated in development and DNA damage response (REDD1) were also prominent. Based on the results obtained from gene expression profiling, we particularly focused on the REDD1/mTOR (mammalian target of rapamycin) pathway in deferasirox‐treated K562 cells, and found an enhanced expression of REDD1 and its down‐stream protein, tuberin (TSC2). Notably, S6 ribosomal protein as well as phosphorylated S6, which is known to be a target of mTOR, was significantly repressed in deferasirox‐treated K562 cells, and REDD1 small interfering RNA restored phosphorylation of S6. Although iron chelation may affect multiple signaling pathways related to cell survival, our data support the conclusion that REDD1 functions up‐stream of tuberin to down‐regulate the mTOR pathway in response to deferasirox. Deferasirox might not only have benefit for iron chelation but also may be an antiproliferative agent in some myeloid leukemias, especially patients who need both iron chelation and reduction of leukemia cells. (Cancer Sci 2009; 100: 970–977)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hypoxia signalling through mTOR and the unfolded protein response in cancer
Wouters, B. G., & Koritzinsky, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2501 · Cited by 894
Forging a field: the golden age of iron biology.
Andrews, N. C. (2008) · Blood · doi:10.1182/blood-2007-12-077388 · Cited by 623
Identification of a Novel Hypoxia-Inducible Factor 1-Responsive Gene, RTP801 , Involved in Apoptosis
Shoshani, T., Faerman, A., Mett, I., Zelin, E., Tenne, T., Gorodin, S., Moshel, Y., Elbaz, S., Budanov, A., Chajut, A., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.7.2283-2293.2002 · Cited by 546
Regulation of iron acquisition and storage: consequences for iron-linked disorders
De Domenico, I., McVey Ward, D., & Kaplan, J. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2295 · Cited by 464
Wang, H., Kubica, N., Ellisen, L. W., Jefferson, L. S., & Kimball, S. R. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m610023200 · Cited by 262
Corradetti, M. N., Inoki, K., & Guan, K.-L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c400557200 · Cited by 237
Chelators at the cancer coalface: Desferrioxamine to Triapine and beyond
Yu, Y., Wong, J., Lovejoy, D. B., Kalinowski, D. S., & Richardson, D. R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1954 · Cited by 195
Jin, H.-O., An, S., Lee, H.-C., Woo, S.-H., Seo, S.-K., Choe, T.-B., Yoo, D.-H., Lee, S.-B., Um, H.-D., & Lee, S.-J. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2006.12.014 · Cited by 91
Choudhari, S. R., Khan, M. A., Harris, G., Picker, D., Jacob, G. S., Block, T., & Shailubhai, K. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0561 · Cited by 90
Iron regulates T-lymphocyte sensitivity to the IFN-γ/STAT1 signaling pathway in vitro and in vivo
Regis, G., Bosticardo, M., Conti, L., De Angelis, S., Boselli, D., Tomaino, B., Bernabei, P., Giovarelli, M., & Novelli, F. (2005) · Blood · doi:10.1182/blood-2004-07-2686 · Cited by 50
Cited by
Iron homeostasis and oxidative stress: An intimate relationship
Galaris, D., Barbouti, A., & Pantopoulos, K. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.118535 · Cited by 903
Regulators of Iron Homeostasis: New Players in Metabolism, Cell Death, and Disease
Bogdan, A. R., Miyazawa, M., Hashimoto, K., & Tsuji, Y. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.11.012 · Cited by 893
Oxidative Stress: Signaling Pathways, Biological Functions, and Disease
Liu, S., Liu, J., Wang, Y., Deng, F., & Deng, Z. (2025) · MedComm · doi:10.1002/mco2.70268 · Cited by 359
Anticancer activity of new coumarin substituted hydrazide–hydrazone derivatives
Nasr, T., Bondock, S., & Youns, M. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.02.026 · Cited by 334
Gallium and its competing roles with iron in biological systems
Chitambar, C. R. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.04.027 · Cited by 274
Metadata
- Authors
- Ohyashiki, J. H., Kobayashi, C., Hamamura, R., Okabe, S., Tauchi, T., & Ohyashiki, K.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2009-04-16
- Volume
- 100
- Issue
- 5
- Pages
- 970-977
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W2079639660
- Cited by
- 131
- References
- 10
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. https://app.cochat.ai/papers/10.1111/j.1349-7006.2009.01131.x
- The paper
- Ohyashiki, J. H., Kobayashi, C., Hamamura, R., Okabe, S., Tauchi, T., & Ohyashiki, K. (2009). The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Science. https://doi.org/10.1111/j.1349-7006.2009.01131.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.